Profile data is unavailable for this security.
About the company
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. It markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel), and LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel). ZYNTEGLO is the first gene therapy for the treatment of adult and pediatric patients with ß-thalassemia who require regular red blood cell transfusions. SKYSONA is used to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). LYFGENIA was approved by the FDA for the treatment of patients 12 years of age or older with sickle cell disease (SCD) and a history of vaso-occlusive events (VOEs). It is focused on pursuing curative gene therapies.
- Revenue in USD (TTM)54.90m
- Net income in USD-311.44m
- Incorporated1992
- Employees375.00
- Locationbluebird bio Inc455 Grand Union BoulevardSOMERVILLE 02145United StatesUSA
- Phone+1 (339) 499-9300
- Fax+1 (302) 636-5454
- Websitehttps://www.bluebirdbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incannex Healthcare Inc | 12.00k | -18.46m | 48.87m | 9.00 | -- | 3.92 | -- | 4,072.55 | -1.14 | -1.14 | 0.0007 | 0.7067 | 0.0003 | -- | 0.0024 | 1,333.33 | -48.51 | -130.12 | -54.36 | -148.24 | -- | -- | -153,833.30 | -3,421.98 | -- | -- | 0.00 | -- | -- | 61.03 | 62.18 | -- | 73.79 | -- |
| United-Guardian, Inc. | 12.31m | 3.25m | 49.57m | 25.00 | 15.27 | 4.09 | 14.80 | 4.03 | 0.7065 | 0.7065 | 2.68 | 2.64 | 0.9575 | 4.12 | 7.65 | 492,387.20 | 25.25 | 29.84 | 28.67 | 34.39 | 50.66 | 55.31 | 26.37 | 28.79 | 6.99 | -- | 0.00 | 97.37 | -14.28 | -4.14 | 0.4616 | -9.92 | 17.19 | -19.73 |
| SCYNEXIS Inc | 8.57m | -36.44m | 49.59m | 29.00 | -- | 0.8493 | -- | 5.79 | -0.756 | -0.756 | 0.177 | 1.54 | 0.0692 | -- | 3.61 | 295,379.30 | -29.44 | -30.02 | -35.54 | -36.35 | -71.42 | -- | -425.41 | -86.76 | -- | -- | 0.1843 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| Odonate Inc | 0.00 | -102.07m | 49.87m | 137.00 | -- | 1,839.01 | -- | -- | -13.59 | -13.59 | 0.00 | 9.27 | 0.00 | -- | -- | 0.00 | -66.98 | -58.36 | -83.00 | -65.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | -- | -- |
| Immix Biopharma Inc | 0.00 | -19.02m | 51.06m | 14.00 | -- | 2.14 | -- | -- | -0.8411 | -0.8411 | 0.00 | 0.871 | 0.00 | -- | -- | 0.00 | -86.64 | -- | -100.82 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
| Aadi Bioscience Inc | 25.07m | -61.69m | 52.31m | 53.00 | -- | 0.7595 | -- | 2.09 | -2.29 | -2.29 | 0.9285 | 2.80 | 0.2225 | 0.696 | 4.09 | 281,685.40 | -54.75 | -50.25 | -65.27 | -56.15 | 87.39 | -- | -246.06 | -473.97 | 4.54 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
| BGM Group Ltd | 29.87m | -7.86m | 52.83m | 298.00 | -- | 1.20 | -- | 1.77 | -1.10 | -1.10 | 4.18 | 6.07 | 0.5237 | 3.73 | 25.96 | 100,236.40 | -14.43 | 2.71 | -17.01 | 3.86 | 2.92 | 11.66 | -27.56 | 2.72 | 6.06 | -0.7527 | 0.00 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
| CASI Pharmaceuticals Inc | 23.10m | -27.21m | 73.45m | 176.00 | -- | 8.14 | -- | 3.18 | -2.03 | -2.03 | 1.72 | 0.6731 | 0.3577 | 0.8917 | 2.39 | 131,250.00 | -41.56 | -34.75 | -62.38 | -46.91 | 56.81 | 55.98 | -116.17 | -153.72 | 2.36 | -- | 0.6718 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
| bluebird bio Inc | 54.90m | -311.44m | 78.67m | 375.00 | -- | 1.48 | -- | 1.43 | -2.19 | -2.19 | 0.3574 | 0.2733 | 0.0909 | 3.21 | -- | 146,400.00 | -51.54 | -34.75 | -80.31 | -40.84 | -37.34 | -124.35 | -567.29 | -5,770.41 | 0.5712 | -19.81 | 0.7827 | -- | 720.04 | -11.58 | 8.00 | -- | -30.47 | -- |
| Assertio Holdings Inc | 132.19m | -345.11m | 81.04m | 53.00 | -- | 0.6132 | -- | 0.613 | -4.11 | -4.11 | 1.44 | 1.39 | 0.3862 | 1.27 | 3.24 | 2,494,076.00 | -100.82 | -21.51 | -134.56 | -32.05 | 72.12 | 88.68 | -261.08 | -62.10 | 1.51 | -- | 0.2266 | -- | -2.67 | -13.38 | -402.80 | -- | -28.25 | -- |
| Journey Medical Corp | 77.68m | 843.00k | 83.21m | 58.00 | 56.28 | 10.01 | 20.29 | 1.07 | -0.0131 | -0.0131 | 3.91 | 0.5642 | 1.15 | 2.36 | 5.71 | 1,339,328.00 | 1.25 | -- | 5.17 | -- | 66.79 | -- | 1.09 | -- | 1.08 | 2.00 | 0.6682 | -- | 7.48 | -- | 87.00 | -- | -- | -- |
| Cellectar Biosciences Inc | 0.00 | -48.74m | 86.00m | 20.00 | -- | 16.75 | -- | -- | -2.51 | -2.51 | 0.00 | 0.3839 | 0.00 | -- | -- | 0.00 | -271.59 | -83.69 | -682.65 | -99.80 | -- | -- | -- | -- | -- | -41.97 | 0.00 | -- | -- | -- | -32.80 | -- | 17.55 | -- |
| Zhong Yuan Bio-Technology Holdings Ltd | 2.49m | 232.02k | 88.22m | 35.00 | 391.37 | 348.44 | -- | 35.38 | 0.0128 | -0.0176 | 0.1395 | 0.0143 | 0.8583 | -1.61 | 3.25 | 71,253.43 | 6.49 | -- | 19.10 | -- | 106.30 | -- | 7.57 | -- | 0.8309 | 2.53 | 0.8593 | -- | -28.60 | -- | -148.37 | -- | -- | -- |
| I-Mab ADR | -100.00bn | -100.00bn | 88.97m | 220.00 | -- | 0.3786 | -- | -- | -- | -- | -- | 2.91 | -- | -- | -- | -- | -- | -35.51 | -- | -41.43 | -- | -- | -- | -509.54 | -- | -- | 0.00 | -- | 111.86 | -13.65 | 44.45 | -- | -5.95 | -- |
Data as of Nov 08 2024. Currency figures normalised to bluebird bio Inc's reporting currency: US Dollar USD
29.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Jun 2024 | 14.26m | 7.35% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 10.47m | 5.40% |
| Columbia Wanger Asset Management LLCas of 30 Jun 2024 | 6.38m | 3.29% |
| Millennium Management LLCas of 30 Jun 2024 | 5.15m | 2.65% |
| Palo Alto Investors LPas of 30 Jun 2024 | 4.63m | 2.39% |
| Geode Capital Management LLCas of 30 Jun 2024 | 4.52m | 2.33% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 3.80m | 1.96% |
| ACATIS Investment Kapitalverwaltungsgesellschaft mbHas of 31 Aug 2024 | 3.30m | 1.70% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 2.28m | 1.18% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 1.62m | 0.83% |
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
